Harvard University researchers have identified a unique characteristic of the resistant cancer cells, which could lead to an inhibitor can be repurposed and combined with chemotherapy to improve patient outcomes.
A new technique called ELeCt (erythrocyte-leveraged chemotherapy) can transport drug-loaded nanoparticles into cancerous lung tissue by mounting them on the body’s own red blood cells.
Every year, more than 18 million people around the world are told, “You have cancer.” In the U.S., nearly half of all men and more than one-third of women will develop some kind of cancer during their lifetimes, and 600,000-plus die from it annually. Despite the billions of dollars and countless new treatments that have […]
Emily Balskus and a team of researchers untangled how soil bacteria are able to manufacture streptozotocin, an antibiotic and anti-cancer compound.
/
1
